NATCOPHARM:NSE-Natco Pharma Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 647.35

Change

0.00 (0.00)%

Market Cap

INR 118.25B

Volume

1.28M

Avg Analyst Target

INR 848.00 (+31.00%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


NATCOPHARM Stock Forecast & Price:
Based on the Natco Pharma Limited stock forecasts from 4 analysts, the average analyst target price for Natco Pharma Limited is INR 848.00 over the next 12 months. Natco Pharma Limited’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Natco Pharma Limited is Bearish, which is based on 4 positive signals and 10 negative signals. At the last closing, Natco Pharma Limited’s stock price was INR 647.35. Natco Pharma Limited’s stock price has changed by -13.66% over the past week, -0.41% over the past month and -34.52% over the last year.

About Natco Pharma Limited (NATCOPHARM:NSE)

NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovar ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-14 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

N/A

INR2,191.67B 56.39 28.73
DIVISLAB:NSE Divi's Laboratories Limited

N/A

INR989.19B 33.41 25.55
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

N/A

INR709.90B 23.93 13.20
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

N/A

INR523.65B 65.42 25.61
PEL:NSE Piramal Enterprises Limited

N/A

INR427.41B 22.81 11.63
ALKEM:NSE Alkem Laboratories Limited

N/A

INR355.67B 21.61 21.38
AUROPHARMA:NSE Aurobindo Pharma Limited

N/A

INR347.73B 13.13 7.15
LUPIN:NSE Lupin Limited

N/A

INR310.45B 25.10 -92.56
LAURUSLABS:NSE Laurus Labs Limited

N/A

INR304.23B 36.46 21.64
IPCALAB:NSE IPCA Laboratories Limited

N/A

INR235.45B 32.68 20.48

ETFs Containing NATCOPHARM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -28.44% 24% F 17% F
Dividend Return 0.22% 10% F 10% F
Total Return -28.22% 25% F 17% F
Trailing 12 Months  
Capital Gain -34.52% 22% F 9% F
Dividend Return 0.46% 50% F 26% F
Total Return -34.06% 23% F 9% F
Trailing 5 Years  
Capital Gain -12.34% 28% F 36% F
Dividend Return 3.66% 58% F 49% F
Total Return -8.68% 28% F 36% F
Average Annual (5 Year Horizon)  
Capital Gain 4.31% 15% F 30% F
Dividend Return 0.71% 73% C 51% F
Total Return 5.02% 17% F 30% F
Risk Return Profile  
Volatility (Standard Deviation) 34.03% 80% B- 79% C+
Risk Adjusted Return 14.75% 20% F 32% F
Market Capitalization 118.25B 82% B- 84% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 28.44 35% F 37% F
Price/Book Ratio 2.74 51% F 39% F
Price / Cash Flow Ratio 254.30 3% F 3% F
EV/EBITDA 16.97 36% F 30% F
Management Effectiveness  
Return on Equity 4.05% 26% F 29% F
Return on Invested Capital 1.96% 18% F 30% F
Return on Assets 1.53% 22% F 31% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield 0.67% 46% F 39% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.67 60% D- 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector